CA-MOVEWORKS
Moveworks, the leading AI copilot platform for the enterprise, today announced registration for its annual Moveworks.global conference is now open. The event will take place on April 23, 2024, and will be held both virtually and in-person in San Jose, CA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222535446/en/
In an era where artificial intelligence is not just an advantage but a necessity, Moveworks.global is the must-attend event for industry leaders, developers, and forward-thinkers eager to explore the transformative power of generative AI in business. This event serves as a dynamic platform for participants to engage with the brightest minds in the industry.
With past speakers from world-renowned companies like OpenAI, Salesforce, Honeywell, and more, attendees will learn firsthand how best-in-class organizations are leveraging generative AI to foster unprecedented levels of business agility. From global corporations to smaller enterprises eager to harness the potential of generative AI, Moveworks.global promises to offer invaluable insights for leveraging AI to gain a competitive edge.
Event highlights include:
- Unlocking productivity: Discover the untapped potential of centralizing search and action to streamline operations while enhancing productivity.
- AI adaptability through reasoning: Learn why advanced AI reasoning capabilities are crucial for creating adaptable, intelligent systems that can meet evolving business needs.
- Custom AI solutions: Gain practical knowledge on customizing AI tools to align with specific business processes — accelerating growth and innovation.
- Continuous improvement: Hear success stories and proven strategies from various industries on driving continuous service improvement through AI.
Whether you're aiming to integrate AI into your organization or develop AI-driven solutions, Moveworks.global will open new horizons and inspire actionable strategies for leveraging generative AI within the enterprise.
“Moveworks.global is more than just a conference — it's a catalyst for transformative change with AI,” said Bhavin Shah, CEO and founder of Moveworks. “This year, we're zeroing in on tangible generative AI successes, showcasing actual outcomes and practical frameworks from industry pioneers. It's a unique opportunity to learn from those who've turned their AI visions into reality.”
Join us at Moveworks.global to be at the forefront of the AI revolution in business. Register today to secure your place among leaders pioneering the future of enterprise AI.
For more information and to register, visit: https://global.moveworks.com/2024.
About Moveworks
Moveworks is the leading AI copilot platform for the enterprise. It empowers the workforce to interact with and take action across all business systems through natural language. Powered by the world’s most advanced LLMs and our proprietary MoveLM model, the Moveworks copilot enables users to search information, take action, automate tasks, and generate factually accurate content with generative AI. Companies such as Databricks, Broadcom, Hearst, and Toyota North America leverage Moveworks' out-of-the-box solutions and intuitive developer tools to automate L1 support, enhance the employee experience, and accelerate business transformation.
Founded in 2016, Moveworks has raised $315 million in funding, at a valuation of $2.1 billion. In 2023, it was named to the Forbes Cloud 100 list — a definitive list of the top private cloud companies in the world — and has been included in Forbes’ AI 50 list for five consecutive years.
For more information, visit: Moveworks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222535446/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom